AGA Family of Websites: Gastro.org
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
Game plan. Also available in XXXL resolution
  April 5, 2021

Your game plan for helping IBD patients with COVID-19

AGA’s free course reviews the GI field’s current understanding about COVID-19 along with current treatment guidelines on the virus.
Share on facebook
Share on twitter
Share on linkedin
Share on email

As the medical community has learned, COVID-19 can dramatically impact the GI tract from abdominal pain to loss of appetite to diarrhea. So, what does that mean for people suffering from inflammatory bowel disease (IBD)? AGA’s free course, APP Pharmacology: IBD Series – Biologics, reviews the GI field’s current understanding about COVID-19, its impact on IBD patients and current treatment guidelines on the virus. In addition, the course focuses on key biologic and oral small-molecule treatments for IBD. Learn the dosing, pharmacokinetics and side effects for:

  • TNF antagonist (anti-TNF).
  • Anti-integrin.
  • Interleukin.
  • Janus Kinase (JAK) inhibitor.

Led by nationally-recognized clinical nurse practitioners, you will be guided through case-based scenarios designed to help you identify which biologic therapies are best suited for your patients. And, as your expertise grows, so will your value to your patient care team.

This program was supported by independent educational grants from Gilead Sciences, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Your hub for GI education is
AGA University
Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.

X